Agenus Inc. (NASDAQ:AGEN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Agenus Inc. (NASDAQ:AGEN) have received a consensus recommendation of “Hold” from the five ratings firms that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have assigned a buy recommendation to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $14.50.

Several equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Agenus in a research note on Monday, December 29th. Wall Street Zen lowered Agenus from a “buy” rating to a “hold” rating in a research report on Sunday.

Agenus Stock Performance

Shares of Agenus stock opened at $3.34 on Friday. The firm has a fifty day moving average of $3.20 and a two-hundred day moving average of $3.70. The stock has a market capitalization of $128.25 million, a price-to-earnings ratio of -7.26 and a beta of 1.56. Agenus has a 52 week low of $1.38 and a 52 week high of $7.34.

Agenus (NASDAQ:AGEN) last posted its quarterly earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.27) by $1.83. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.The business had revenue of $34.20 million for the quarter, compared to analyst estimates of $28.10 million. As a group, research analysts forecast that Agenus will post -12.55 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of AGEN. Renaissance Technologies LLC raised its holdings in Agenus by 721.1% in the fourth quarter. Renaissance Technologies LLC now owns 543,546 shares of the biotechnology company’s stock worth $1,707,000 after purchasing an additional 477,346 shares during the period. Marshall Wace LLP acquired a new position in shares of Agenus in the 2nd quarter valued at $1,976,000. AQR Capital Management LLC grew its holdings in shares of Agenus by 3,080.3% in the 1st quarter. AQR Capital Management LLC now owns 441,486 shares of the biotechnology company’s stock valued at $664,000 after buying an additional 427,604 shares during the period. Bank of America Corp DE increased its position in shares of Agenus by 110.0% in the 2nd quarter. Bank of America Corp DE now owns 420,678 shares of the biotechnology company’s stock valued at $1,922,000 after buying an additional 220,327 shares in the last quarter. Finally, Walleye Capital LLC acquired a new stake in Agenus during the 2nd quarter worth $906,000. Institutional investors and hedge funds own 61.46% of the company’s stock.

About Agenus

Agenus, Inc (NASDAQ:AGEN) is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system’s response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus’ pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.